Skip to main content

Table 1 Univariate analysis (log rank test)

From: Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

Patient characteristics

Total (%) n = 464

Deceased (% of the total)

Median (IQR) survival (months)

p value

Gender

   

0.56

 Male

353 (76)

292 (83)

14.2 (7.0-29.5)

 

 Female

111 (24)

100 (90)

14.2 (9.3-28.9)

 

Age (by quartile)

   

0.84

  < 54 years

112 (24)

96 (86)

13.7 (7.7-28.8)

 

 54-60 years

112 (24)

95 (85)

13.5 (8.4-30.1)

 

 60-67 years

117 (25)

96 (82)

15.6 (7.3-30.1)

 

  ≥ 67 years

123 (27)

105 (85)

13.8 (6.9-27.9)

 

Performance status

   

4.10−4

 0

183 (39)

149 (81)

16.8 (10.3-35.5)

 

 1

261 (56)

224 (86)

12.2 (6.4-28.0)

 

 2

20 (4)

19 (95)

6.0 (2.8-13.9)

 

Charlson comorbidity index[[18]]

   

0.71

 0

378 (81)

321 (85)

13.6 (7.3-28.9)

 

  ≥ 1

86 (19)

71 (83)

15.3 (7.3-29.5)

 

Histology

   

<10−4

 Adenocarcinoma

279 (60)

247 (89)

13.7 (7.1-27.9)

 

 Squamous cell carcinoma

112 (24)

79 (71)

20.2 (9.2-63.5)

 

 Large cell carcinoma

73 (16)

66 (90)

10.5 (6.3-20.2)

 

Cancer spread

   

<10−4

 Localised (II IIIA)

83 (18)

49 (59)

35.5 (18.5-not reached)

 

 Advanced (IIIB)

97 (21)

75 (87)

20.2 (10.8-41.5)

 

 Metastatic (IV)

284 (61)

268 (94)

10.5 (5.9-18.6)

 

Platinum-based doublet

   

0.26

 Platinum-gemcitabine

179 (39)

150 (84)

15.8 (8.0-33.2)

 

 Platinum-vinorelbine

77 (17)

64 (82)

15.2 (8.3-28.9)

 

 Platinum-docetaxel

74 (16)

64 (86)

12.7 (7.3-21.8)

 

 Platinum-paclitaxel

70 (15)

61 (87)

11.3 (4.3-26.9)

 

 Platinum-pemetrexed

64 (14)

54 (84)

16.0 (8.1-29.9)

 

Tumour response

   

<10−4

 Complete/partial response

146 (31)

108 (74)

20.8 (10.8-43.9)

 

 Stable disease

245 (53)

213 (87)

14.6 (8.2-28.8)

 

 Progressive disease

73 (16)

71 (97)

4.5 (2.7-8.3)

 
  1. IQR: interquartile range.